[Publication] AHCC®can support immune function to eradicate persistent Human Papillomavirus Infections


Results from a randomized, double-blind, placebo-controlled Phase II study by researchers at UTHealth Houston, conducted with a grant from the National Institutes of Health (NIH), were published in the prestigious peer-reviewed journal “Frontiers in Oncology”. The paper reported that AHCC® could support the immune system in clearing persistent HPV infections in two-thirds of study participants after six months of supplementation.

Currently no treatment for HPV infection is available and people infected with high-risk HPV need to wait and see how the infection goes. The results provide hopeful prospect to them.

Open access link to the paper:
Official announcement from the University of Texas: